Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joan Maurel

Showing results (41-50 of 116) with videos related to

Pageof 12
Sort By:
Gastroenterologia Y Hepatologia|September 21, 2010
[Incidence and characteristics of pancreatic cystic neoplasms]Ana Adet, Rosa Miquel, Josep A Bombi, et al.
Journal of Surgical Oncology|September 24, 2004
Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS)Joan Maurel, José Buesa, Antonio López-Pousa, et al.
Cancer|March 26, 2004
Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS)Joan Maurel, Joaquín Fra, Antonio López-Pousa, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 3, 2012
A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancerCristina Gravalos, Antonieta Salut, Carlos García-Girón, et al.
Medicina Clinica|October 12, 2016
[Recommendations for the diagnosis, staging and treatment of pre-malignant lesions and pancreatic adenocarcinoma]Marta Martin-Richard, Angels Ginès, Juan Ramón Ayuso, et al.
The Oncologist|March 29, 2014
An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancerRocio Garcia-Carbonero, Fernando Rivera, Joan Maurel, et al.
Annals of Surgical Oncology|March 5, 2009
Serum matrilysin levels predict outcome in curatively resected colorectal cancer patientsAlejandro Martínez-Fernandez, Xabier García-Albeniz, Estela Pineda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2005
Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trialFrancisco Rodríguez-Moranta, Joan Saló, Angels Arcusa, et al.
Medicina Clinica|March 19, 2011
[Malignancy predictive factors in pancreatic intraductal papillary mucinous neoplasm]Ana Celia Adet Caldelari, Rosa Miquel, Josep Antoni Bombi, et al.
Gastrointestinal Endoscopy|August 2, 2011
EUS and magnetic resonance imaging in the staging of rectal cancer: a prospective and comparative studyGlòria Fernández-Esparrach, Juan R Ayuso-Colella, Oriol Sendino, et al.
Pageof 12

Showing results (41-50 of 116) with videos related to

Sort By:
Pageof 12
Gastroenterologia Y Hepatologia|September 21, 2010
[Incidence and characteristics of pancreatic cystic neoplasms]Ana Adet, Rosa Miquel, Josep A Bombi, et al.
Journal of Surgical Oncology|September 24, 2004
Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS)Joan Maurel, José Buesa, Antonio López-Pousa, et al.
Cancer|March 26, 2004
Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS)Joan Maurel, Joaquín Fra, Antonio López-Pousa, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 3, 2012
A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancerCristina Gravalos, Antonieta Salut, Carlos García-Girón, et al.
Medicina Clinica|October 12, 2016
[Recommendations for the diagnosis, staging and treatment of pre-malignant lesions and pancreatic adenocarcinoma]Marta Martin-Richard, Angels Ginès, Juan Ramón Ayuso, et al.
The Oncologist|March 29, 2014
An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancerRocio Garcia-Carbonero, Fernando Rivera, Joan Maurel, et al.
Annals of Surgical Oncology|March 5, 2009
Serum matrilysin levels predict outcome in curatively resected colorectal cancer patientsAlejandro Martínez-Fernandez, Xabier García-Albeniz, Estela Pineda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2005
Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trialFrancisco Rodríguez-Moranta, Joan Saló, Angels Arcusa, et al.
Medicina Clinica|March 19, 2011
[Malignancy predictive factors in pancreatic intraductal papillary mucinous neoplasm]Ana Celia Adet Caldelari, Rosa Miquel, Josep Antoni Bombi, et al.
Gastrointestinal Endoscopy|August 2, 2011
EUS and magnetic resonance imaging in the staging of rectal cancer: a prospective and comparative studyGlòria Fernández-Esparrach, Juan R Ayuso-Colella, Oriol Sendino, et al.
Pageof 12